Lauren M. Green | Authors

June 16, 2017

Patients receiving treatment for metastatic cancer who used a web-based tool to report their symptoms either while at home or during clinic visits lived on average 5 months longer than their counterparts who had standard symptom monitoring.

June 06, 2017

Larotrectinib (LOXO-101), the novel pan-TRK inhibitor, induced responses in 3 out of 4 patients with a TRK fusion–positive solid tumor, according to findings presented in a press conference June 3 at the 2017 ASCO Annual Meeting.

May 18, 2017

Eating tree nuts, like almonds, walnuts, and pecans can improve overall survival and reduce the risk of recurrence in patients with colon cancer, findings of a new prospective study suggest.

May 10, 2017

The FDA has given its approval to co-packaging of the oral medications ribociclib (Kisqali) and letrozole (Femara) for the treatment of postmenopausal women with HR-positive, HER2-negative advanced breast cancer.

April 07, 2017

Adding a formulation of the Coxsackievirus A21 to ipilimumab yielded an overall response rate of 50% and was well-tolerated in immunotherapy-naïve and pretreated patients with advanced melanoma.

April 06, 2017

According to 5-year follow-up data from the CA209-003 study, long-term survival in patients with metastatic non–small cell lung cancer (NSCLC) who received the immune checkpoint inhibitor nivolumab (Opdivo) has proven to be much higher than expected, with 16% of patients surviving after 5 years.